It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Visceral adiposity is a risk factor for severe COVID-19, and a link between adipose tissue infection and disease progression has been proposed. Here we demonstrate that SARS-CoV-2 infects human adipose tissue and undergoes productive infection in fat cells. However, susceptibility to infection and the cellular response depends on the anatomical origin of the cells and the viral lineage. Visceral fat cells express more ACE2 and are more susceptible to SARS-CoV-2 infection than their subcutaneous counterparts. SARS-CoV-2 infection leads to inhibition of lipolysis in subcutaneous fat cells, while in visceral fat cells, it results in higher expression of pro-inflammatory cytokines. Viral load and cellular response are attenuated when visceral fat cells are infected with the SARS-CoV-2 gamma variant. A similar degree of cell death occurs 4-days after SARS-CoV-2 infection, regardless of the cell origin or viral lineage. Hence, SARS-CoV-2 infects human fat cells, replicating and altering cell function and viability in a depot- and viral lineage-dependent fashion.
Visceral adiposity is a risk factor for severe COVID-19, and infection of adipose tissue by SARS-CoV-2 has been reported. Here the authors confirm that human adipose tissue is a possible site for SARS-CoV-2 infection, but the degree of adipose tissue infection and the way adipocytes respond to the virus depend on the adipose tissue depot and the viral strain.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


















1 Institute of Biology, University of Campinas, Department of Biochemistry and Tissue Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
2 University of São Paulo, Department of Cell and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, Ribeirão Preto, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
3 University of São Paulo, Department of Pharmacology, Ribeirão Preto Medical School, Ribeirão Preto, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); Center for Research in Inflammatory Diseases, Ribeirão Preto, Brazil (GRID:grid.11899.38)
4 University of Campinas, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
5 Brazilian Center for Research in Energy and Materials (CNPEM), Brazilian Biosciences National Laboratory (LNBio), Campinas, Brazil (GRID:grid.452567.7) (ISNI:0000 0004 0445 0877)
6 University of São Paulo, Department of Pharmacology, Ribeirão Preto Medical School, Ribeirão Preto, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); Center for Research in Inflammatory Diseases, Ribeirão Preto, Brazil (GRID:grid.11899.38); University of São Paulo, Department of Biomolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, Ribeirão Preto, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
7 Center for Research in Inflammatory Diseases, Ribeirão Preto, Brazil (GRID:grid.11899.38); Faculty of Medical Sciences, University of Campinas, Department of Pharmacology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
8 University of Campinas, Hematology-Hemotherapy Center, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
9 University of São Paulo, Virology Research Center, Ribeirão Preto Medical School, Ribeirão Preto, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
10 University of São Paulo, Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, Ribeirão Preto, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
11 Brazilian National Cancer Institute (INCA), Laboratory of Bioinformatics and Computational Biology, Division of Experimental and Translational Research, Rio de Janeiro, Brazil (GRID:grid.419166.d)
12 Institute of Biology, University of Campinas, Department of Biochemistry and Tissue Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
13 Brazilian National Cancer Institute (INCA), Laboratory of Bioinformatics and Computational Biology, Division of Experimental and Translational Research, Rio de Janeiro, Brazil (GRID:grid.419166.d); University of Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
14 University of Campinas, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
15 University of Tartu, Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)
16 University of Campinas, Department of Surgery, Faculty of Medical Sciences, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
17 University of Campinas, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
18 Institute of Biology, University of Campinas, Department of Biochemistry and Tissue Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); D’Or Institute for Research and Education (IDOR), São Paulo, Brazil (GRID:grid.472984.4); Conselho Nacional de Desenvolvimento Científico e Tecnológico, Instituto Nacional de Biomarcadores em Neuropsiquiatria, São Paulo, Brazil (GRID:grid.450640.3) (ISNI:0000 0001 2189 2026)
19 Institute of Biology, University of Campinas, Department of Biochemistry and Tissue Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Conselho Nacional de Desenvolvimento Científico e Tecnológico, Instituto Nacional de Obesidade e Diabetes, Campinas, Brazil (GRID:grid.450640.3) (ISNI:0000 0001 2189 2026)